IA
ONCT

IFP Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

IFP Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1
Closed – – 3583
2018
Q4 		$0 Hold
1
– – ﹤0.01% 3937
2018
Q3 		$0 Hold
1
– – ﹤0.01% 4058
2018
Q2 		$2K Hold
1
– – ﹤0.01% 3650
2018
Q1 		$2K Hold
1
– – ﹤0.01% 3561
2017
Q4 		$2K Sell
1
-9
-90% -$13K ﹤0.01% 3612
2017
Q3 		$11K Hold
10
– – ﹤0.01% 2979
2017
Q2 		$7K Hold
10
– – ﹤0.01% 3251
2017
Q1 		$7K Hold
10
– – ﹤0.01% 3157
2016
Q4 		$7K Buy
10
+1
+11% +$1.07K ﹤0.01% 3148
2016
Q3 		$10K Hold
9
– – ﹤0.01% 2855
2016
Q2 		$7K Buy
+9
New +$8.41K ﹤0.01% 2973
2016
Q1 		– Sell
-8
Closed -$8K – 3574
2015
Q4 		$8K Buy
+8
New +$10.6K ﹤0.01% 2718

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IFP Advisors's ONCT Position: Q1 2019 in Review

IFP Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2019, closing a stake of 1 share.

IFP Advisors first reported a position in ONCT in Q4 2015 and held it in 12 quarters. The position peaked at $11K in Q3 2017. 35 funds tracked by Wall St. Rank hold ONCT as of Q1 2019.

  • IFP Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • IFP Advisors sold 1 Oncternal Therapeutics, Inc. Common Stock share in Q1 2019.
  • IFP Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2015 and held it in 12 quarters.
  • IFP Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $11K in Q3 2017.
  • 35 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2019.

Based on IFP Advisors's 13F filing for Q1 2019, filed 15 May 2019.